Your browser doesn't support javascript.
loading
The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis.
Cisneros-Garza, L E; González-Huezo, M S; Moctezuma-Velázquez, C; Ladrón de Guevara-Cetina, L; Vilatobá, M; García-Juárez, I; Alvarado-Reyes, R; Álvarez-Treviño, G A; Allende-Pérez, S; Bornstein-Quevedo, L; Calderillo-Ruiz, G; Carrillo-Martínez, M A; Castillo-Barradas, M; Cerda-Reyes, E; Félix-Leyva, J A; Gabutti-Thomas, J A; Guerrero-Ixtlahuac, J; Higuera-de-la-Tijera, F; Huitzil-Meléndez, D; Kimura-Hayama, E; López-Hernández, P A; Malé-Velázquez, R; Méndez-Sánchez, N; Morales-Ruiz, M A; Ruíz-García, E; Sánchez-Ávila, J F; Torrecillas-Torres, L.
Afiliação
  • Cisneros-Garza LE; Hospital Christus Muguerza Alta Especialidad, Monterrey, Nuevo León, Mexico.
  • González-Huezo MS; Centro Médico Issemym, Metepec, Estado de México, Mexico. Electronic address: laura_cisneros@yahoo.com.
  • Moctezuma-Velázquez C; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Ladrón de Guevara-Cetina L; Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico.
  • Vilatobá M; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • García-Juárez I; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Alvarado-Reyes R; Hospital San Vicente, Monterrey, Nuevo León, Mexico.
  • Álvarez-Treviño GA; Unidad de Medicina de Alta Especialidad 25 IMSS, Monterrey, Nuevo León, Mexico.
  • Allende-Pérez S; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Bornstein-Quevedo L; InmunoQ, Laboratorio de Patología, Inmunohistoquímica y Biología Molecular, Mexico City, Mexico.
  • Calderillo-Ruiz G; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Carrillo-Martínez MA; Hospital San José Tec de Monterrey, Monterrey, Nuevo León, Mexico.
  • Castillo-Barradas M; Centro Médico Nacional la Raza IMSS, Mexico City, Mexico.
  • Cerda-Reyes E; Hospital Central Militar, Mexico City, Mexico.
  • Félix-Leyva JA; Centro Médico Nacional Siglo XXI IMSS, Mexico City, Mexico.
  • Gabutti-Thomas JA; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Guerrero-Ixtlahuac J; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Higuera-de-la-Tijera F; Hospital General de México, Mexico City, Mexico.
  • Huitzil-Meléndez D; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Kimura-Hayama E; CTScanner Lomas Altas, Mexico City, Mexico.
  • López-Hernández PA; Unidad de Medicina de Alta Especialidad 25 IMSS, Monterrey, Nuevo León, Mexico.
  • Malé-Velázquez R; Instituto de Salud Digestiva y Hepática SA de CV, Guadalajara, Jalisco, Mexico.
  • Méndez-Sánchez N; Fundación Clínica Médica Sur, Mexico City, Mexico.
  • Morales-Ruiz MA; Centro Oncológico Estatal Issemym, Toluca, Estado de México, Mexico.
  • Ruíz-García E; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Sánchez-Ávila JF; Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico.
  • Torrecillas-Torres L; Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico.
Rev Gastroenterol Mex (Engl Ed) ; 87(2): 216-234, 2022.
Article em En | MEDLINE | ID: mdl-35431142
Hepatocellular carcinoma (HCC) is more frequently manifesting as one of the main complications of cirrhosis of the liver, its principal risk factor. There have been modifications in its incidence over the past decade, related to an epidemiologic transition in the etiology of cirrhosis, with a decrease in the prevalence of hepatitis C and an increase in nonalcoholic fatty liver disease (NAFLD) as a cause, as well as the development of HCC in the non-cirrhotic liver due to NAFLD. Genetic markers associated with the disease have been identified, and surveillance and diagnosis have improved. Regarding treatment, surgical techniques, in both resection and transplantation, have advanced and radiologic techniques, at the curative stage of the disease, have enhanced survival in those patients. And finally, there have been radical changes in the systemic approach, with much more optimistic expectations, when compared with the options available a decade ago. Therefore, the Asociación Mexicana de Hepatología decided to carry out the Second Mexican Consensus on Hepatocellular Carcinoma, which is an updated review of the available national and international evidence on the epidemiology, risk factors, surveillance, diagnosis, and treatment of the disease, to offer the Mexican physician current information on the different topics regarding hepatocellular carcinoma. In this first part of the document, the topics related to epidemiology and diagnosis are presented.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans País como assunto: Mexico Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatopatia Gordurosa não Alcoólica / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans País como assunto: Mexico Idioma: En Ano de publicação: 2022 Tipo de documento: Article